
-
Gilead Sciences NasdaqGS:GILD Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Location: 333 Lakeside Drive, Foster City, CA, 94404, United States | Website: https://www.gilead.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
154.4B
Cash
8.711B
Avg Qtr Burn
N/A
Short % of Float
1.99%
Insider Ownership
0.12%
Institutional Own.
89.64%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Livdelzi (Seladelpar) Details Primary biliary cholangitis, Primary sclerosing cholangitis, Non-alcoholic steatohepatitis , Liver disease | Approved Quarterly sales | |
Trodelvy® (sacituzumab govitecan-hziy) Details Breast cancer, ER+/HER2- breast cancer, Cancer | Approved Quarterly sales | |
Yescarta® Details B-cell lymphoma, Lymphopenia | Approved Quarterly sales | |
Lenacapavir capsid inhibitor (GS-6207) Details Human immunodeficiency virus | Approved Quarterly sales | |
Veklury® (Remdesivir) Details COVID-19 | Approved Quarterly sales | |
Biktarvy Details Human immunodeficiency virus | Approved Quarterly sales | |
Vemlidy (Tenofovir Alafenamide) Details Chronic hepatitis B | Approved Quarterly sales | |
Tecartus® (brexucabtagene autoleucel) (CAR-T) Details B-cell acute lymphoblastic leukemia, Acute lymphoblastic leukemia, Leukemia | Approved Quarterly sales | |
Lenacapavir Details Human immunodeficiency virus | PDUFA Approval decision | |
Anito-cel Details Multiple myeloma | Phase 3 Data readout | |
Trodelvy® (Sacituzumab govitecan-hziy) Details 1L metastatic triple-negative breast cancer (PD-L1-) | Phase 3 Data readout | |
Trodelvy + Keytruda Details Metastatic triple-negative breast cancer (mTNBC) with PD-L1+ tumors | Phase 3 Data readout | |
Obeldesivir (GS-5245) Details COVID-19 | Phase 3 Update | |
Trodelvy® (sacituzumab govitecan-hziy; SG) Details Cancer, Urothelial cancer | Phase 3 Update | |
Sunlenca (Lenacapavir) Details Human immunodeficiency virus | Phase 2/3 Data readout | |
Bulevirtide (Hepcludex®) Details Hepatitis Delta Virus | Phase 2b Update | |
Yescarta Details Lymphopenia, B-cell lymphoma | Phase 2 Update | |
Trodelvy® (sacituzumab govitecan-hziy) comb w/KEYTRUDA® Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Etrumadenant Details Colorectal cancer | Phase 2 Update | |
Sunlenca (Lenacapavir) + Islatravir Details Human immunodeficiency virus | Phase 2 Update | |
Magrolimab+Azacitidine Details High risk myelodysplastic syndromes | Failed Discontinued |